Published on November 20, 2009 at 9:08 AM
POZEN Inc. (NASDAQ: POZN) announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.
“We believe that PA32540 could address the needs of certain patients with cardiovascular disease,” said John Fort, MD, Chief Medical Officer, POZEN. “We look forward to progressing the development of PA32540 through Phase 3 studies, enabling us to bring this potentially important advancement to those who need it.”
Source POZEN Inc.,